US Cuts Could Jeopardize Global Health Innovations, Says Report
Cuts to US global health and research programs for diseases such as AIDS, tuberculosis and malaria risk derailing the innovations crucial to fighting these diseases, according a new report by the Global Health Technologies Coalition.
Cuts to US global health and research programs for diseases such as AIDS, tuberculosis and malaria risk derailing the innovations crucial to fighting these diseases, according a new report by the Global Health Technologies Coalition.
The report asserts that without continued and consistent US investment in global health research - which has so far “helped deliver some of the greatest advances the field has ever seen” - the momentum needed to do drive these advances “over the finish line” will be compromised.
The report will be released at a congressional briefing at noon, Tuesday, February 26, at the Russell Senate Office Building, Washington, DC. An expert panel - including Dr Caroline Ryan, Director of Technical Leadership, Office of the Global AIDS Coordinator, Department of State, PEPFAR (President’s Emergency Plan for AIDS Relief) and Dr Alan Magill, Director of Malaria, Bill & Melinda Gates Foundation - will be speaking at the event.
For more information, contact Katy Lenard (klenard@burnesscommunications.com)
T: +1 301-280-5719
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
